oncomed.com

OncoMed

Advocacy for Breakthroughs in Medicine. Divslide" data-cycle-timeout="3000" data-cycle-speed="300" data-cycle-fx="fade" data-cycle-paused="true" data-cycle-random="true" data-cycle-log="false". To better treat cancer. To improving patient outcomes. On discovering and developing novel therapeutics directed to fundamental biologic pathways thought to drive cancer's growth, resistance, recurrence and metastases in order to improve the treatment of solid tumor cancers. Financial Strength and Value Creation.

http://www.oncomed.com/

OVERVIEW OF oncomed.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

3

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR ONCOMED.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Wednesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 12 reviews

5 star

5

4 star

2

3 star

4

2 star

0

1 star

1

Hey there! Start your review of oncomed.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.1 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128
160x160
192x192

CONTACTS AT ONCOMED.COM

Whois Privacy Service

Whois Privacy Service

PO B●●●●1610

San●●●ego , CA, 92150-1610

US

1.61●●●●2111

wh●●●@emailaddressprotection.com

View this contact

Whois Privacy Service

Whois Privacy Service

PO B●●●●1610

San●●●ego , CA, 92150-1610

US

1.61●●●●2111

wh●●●@emailaddressprotection.com

View this contact

Whois Privacy Service

Whois Privacy Service

PO B●●●●1610

San●●●ego , CA, 92150-1610

US

1.61●●●●2111

wh●●●@emailaddressprotection.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: 2004 April 11
UPDATED: 2013 January 21
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

DOMAIN AGE

20

YEARS
1

MONTHS
5

DAYS

NAME SERVERS

1: ns1.domaindiscover.com
2: ns2.domaindiscover.com

REGISTRAR

TIERRANET INC. D/B/A DOMAINDISCOVER

WHOIS : whois.domaindiscover.com

REFERRED : http://www.domaindiscover.com

CONTENT

PAGES IN
THIS WEBSITE

3

SSL

EXTERNAL LINKS

20

SITE IP

13.57.125.155

LOAD TIME

0.078 sec

SCORE

6.2

PAGE TITLE

OncoMed | oncomed.com Reviews

<META> DESCRIPTION

Advocacy for Breakthroughs in Medicine. Divslide data-cycle-timeout=3000 data-cycle-speed=300 data-cycle-fx=fade data-cycle-paused=true data-cycle-random=true data-cycle-log=false. To better treat cancer. To improving patient outcomes. On discovering and developing novel therapeutics directed to fundamental biologic pathways thought to drive cancer's growth, resistance, recurrence and metastases in order to improve the treatment of solid tumor cancers. Financial Strength and Value Creation.

<META> KEYWORDS

1 overview

2 management

3 board of directors

4 partners

5 careers

6 pipeline

7 science

8 our science

9 our platform

10 publications

CONTENT

Page content here

KEYWORDS ON PAGE

overview,management,board of directors,partners,careers,pipeline,science,our science,our platform,publications,for investors,press releases,events,financial information,stock information,analysts,faqs,investor contact,corporate governance,drug cost facts

SERVER

nginx

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

OncoMed | oncomed.com Reviews

https://oncomed.com

Advocacy for Breakthroughs in Medicine. Divslide" data-cycle-timeout="3000" data-cycle-speed="300" data-cycle-fx="fade" data-cycle-paused="true" data-cycle-random="true" data-cycle-log="false". To better treat cancer. To improving patient outcomes. On discovering and developing novel therapeutics directed to fundamental biologic pathways thought to drive cancer's growth, resistance, recurrence and metastases in order to improve the treatment of solid tumor cancers. Financial Strength and Value Creation.

INTERNAL PAGES

oncomed.com

1

OncoMed Careers

http://www.oncomed.com/Careers.html

OncoMed, a pioneer and leader in the development of novel cancer therapies directed toward tumor initiating cells, also known as “cancer stem cells”, fosters a culture of innovation as the company strives to provide significant alternatives for the treatment of cancer. Headquartered in Redwood City, California, our employees bring a passionate dedication to the advancement of novel treatments for patients with cancer. Manager, Regulatory Operations. Postdoctoral Fellowship, Cancer Biology. Supports submi...

2

Untitled Document

http://www.oncomed.com/site-map.html

3

OncoMed Pharmaceuticals

http://www.oncomed.com/index.html

OncoMed Pharmaceuticals is a clinical-stage biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence. We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. April 29, 2015 in New York City.

UPGRADE TO PREMIUM TO VIEW 0 MORE

TOTAL PAGES IN THIS WEBSITE

3

LINKS TO THIS WEBSITE

triplepointcapital.com

TriplePoint Capital - TriplePoint Ventures

http://www.triplepointcapital.com/track-record/triplepoint-ventures

morphosys.de

Bestehende Partnerschaften | MorphoSys AG

https://www.morphosys.de/partnerschaften/bestehende-partnerschaften

MorphoSys auf einen Blick. Engineering the Medicines of Tomorrow. Discovery, Alliances and Technologies. Kompetent in der Arzneimittelentwicklung. Herstellung, Chemie- und Produktionskontrolle. Investition in die Medikamente von morgen. Im Folgenden sind die Abkommen der MorphoSys AG kurz beschrieben, die spürbare finanzielle Auswirkungen gehabt haben bzw. in zukünftigen Geschäftsjahren haben könnten (in alphabetischer Reihenfolge). MorphoSys und Astellas Pharma. Wurde Ende 2007 eingestellt. Es befin...

cancerstemcellnews.blogspot.com

Cancer Stem Cell News: July 2012

http://cancerstemcellnews.blogspot.com/2012_07_01_archive.html

A Blog of the Cancer Stem Cell Consortium. Cancer Stem Cell News. A blog of news items related to cancer stem cells, with an emphasis on recent research and articles that are openly accessible. Tuesday, July 17, 2012. Companies selectively targeting cancer stem cells. Today, I posted this to Twitter. 3 Innovative Cancer Treatments.But Which Is The Best Bet? GSK $IMUC $VSTM #cancerSC. 8212; Jim Till (@jimtill) July 17, 2012. Links to this post. Labels: cancer stem cells. Subscribe to: Posts (Atom). Search...

cancerstemcellnews.blogspot.com

Cancer Stem Cell News: Companies selectively targeting cancer stem cells

http://cancerstemcellnews.blogspot.com/2012/07/companies-selectively-targeting-cancer.html

A Blog of the Cancer Stem Cell Consortium. Cancer Stem Cell News. A blog of news items related to cancer stem cells, with an emphasis on recent research and articles that are openly accessible. Tuesday, July 17, 2012. Companies selectively targeting cancer stem cells. Today, I posted this to Twitter. 3 Innovative Cancer Treatments.But Which Is The Best Bet? GSK $IMUC $VSTM #cancerSC. 8212; Jim Till (@jimtill) July 17, 2012. Labels: cancer stem cells. Subscribe to: Post Comments (Atom). Search Twitter for...

phase4-partners.com

Phase4 Partners | Portfolio - Active

http://www.phase4-partners.com/portfolio/companies

Small molecules for gastrointestinal diseases (AstraZeneca spin out). View Website. Small molecules for oncology and inflammation. View Website. Small molecules for bacterial infections (Sandoz spin-out). View Website. San Francisco, US. Developing antibodies to cancer stem cells. (NASDAQ: OMED) View Website. Small molecules for bacterial infections. View Website. San Francisco, US. Transdermal drug delivery technology (Alza/J&J spin-out). View Website.

phase4-partners.com

Phase4 Partners | Portfolio - Active

http://www.phase4-partners.com/portfolio

Small molecules for gastrointestinal diseases (AstraZeneca spin out). View Website. Small molecules for oncology and inflammation. View Website. Small molecules for bacterial infections (Sandoz spin-out). View Website. San Francisco, US. Developing antibodies to cancer stem cells. (NASDAQ: OMED) View Website. Small molecules for bacterial infections. View Website. San Francisco, US. Transdermal drug delivery technology (Alza/J&J spin-out). View Website.

textbiz.org

TextBiz: NASDAQ bottom-100 listing

http://textbiz.org/NASDAQworst.html

Switch to exchange: [ NYSE. Composite Index random walk modeling for 2017 (what's this? Click on the images to explore past years. NASDAQ - Week's Worst Performers. Bottom-50 companies by weekly change in stock price (. Link to the company website,. Medical Diagnostic and Testing Equipment. Skypeople Fruit Juice Inc. Fruit and Vegetable Processing. Biotechnology and Medical Research. China Commercial Credit Inc. Spi Energy Co Ltd. Photovoltaic Solar Systems and Equipment. IT Services and Consulting.

UPGRADE TO PREMIUM TO VIEW 13 MORE

TOTAL LINKS TO THIS WEBSITE

20

OTHER SITES

oncome.org

Main Page - Oncome.org.

BiO network is on-line information source for all the areas of biological research, technology, training, and business. Anyone is welcome to contribute to and use the content with maximum freedom. Please visit our sites that are listed in. Some of our sites are. The free encyclopedia of biology. The internet sites directory for biological science, technology, and business. The free Oenomics portal. The Omics home page for everyone. The international portal for biological information for the countries.

oncomed-solutions.com

OncoMed Solutions - Welcome to OncoMed-Solutions!

PET/CT - Refurbished PET/CT. ABT Molecular Imaging, Inc. Cyclotron - ACSI Advanced. Cyclotron Systems, Inc. Nuclear Medicine Software -. MIM Software, Inc. Robotic HIFU - Theraclion. Radiation Therapy - Coline 6. RT Accessories - Unger. Contouring and Reviewing Software. MIM Software, Inc. PET, SPECT, CT - MOLECUBES. Is the only specialised company offering worldwide complete solutions for customers in molecular imaging and oncology for clinical and pre-clinical use. Every effort is made to keep the webs...

oncomed-unsa.blogspot.com

ONCOMED

Circulo de Estudiantes de Medicina Oncológica. Martes, 6 de septiembre de 2011. Cell Phones and Cancer: Is There a Connection? Bret Stetka, MD; Nora D. Volkow, MD. On May 31, 2011 the World Health Organization (WHO) announced their classification of radiofrequency electromagnetic fields emitted from cell phones as "possibly carcinogenic," and more recently published the evidence and rationale supporting their conclusion.[1] Medscape recently spoke with National Institute on Drug Abuse Director (and B...

oncomed.biz

Hover

This user has not enabled any redirections. Hover lets you easily create simple ways to access your digital life.

oncomed.cl

Inicio/Oncovida

Red Nacional de Atención. Qué es el cáncer. Vidared se extiende y suma a Clínica. Universidad de los Andes. Programa de Apoyo Integral. En Oncovida somos tu red de apoyo". Día Mundial contra en cáncer. Convenio Oncovida con Dipreca. Més de la próstata. Somos la red nacional de oncología,desde hoy somos tu red de apoyo. Red Nacional de Atención. No importa donde estés. Nuestra red de apoyo se extiende de Arica a Punta Arenas para entregarte el mejor servicio. Desde celulares: 2 2599 2900.

oncomed.com

OncoMed

Advocacy for Breakthroughs in Medicine. Divslide" data-cycle-timeout="3000" data-cycle-speed="300" data-cycle-fx="fade" data-cycle-paused="true" data-cycle-random="true" data-cycle-log="false". To better treat cancer. To improving patient outcomes. On discovering and developing novel therapeutics directed to fundamental biologic pathways thought to drive cancer's growth, resistance, recurrence and metastases in order to improve the treatment of solid tumor cancers. Financial Strength and Value Creation.

oncomed.com.br

Oncomed Oncologia

oncomed.cz

oncomed manufacturing a.s.

Výrobní linka č. 1. Výrobní linka č. 2. CZ104/1.1.02/94.01259. CZ104/1.1.04/B3.00101. CZ104/1.1.02/94.01259. CZ104/1.1.04/B3.00101. Aktuálně obsazované pracovní pozice. Technolog, Vedoucího validační skupiny. Analytika. Laboranta mikrobiologické laboratoře. Laboranta analytické laboratoře. Více informací naleznete v sekci Kariéra, Pracovní příležitosti nebo kliknutím na odkaz v hlavičce. Nová korporátní brožura k dispozici ZDE. Nové korporátní video k dispozici ZDE.

oncomed.edyd.com

ONCOMED Cancer Ginecológico Virus Papiloma Humano Vacunas Prevención Diagnóstico Ginecología

Oncología Cáncer de Útero: Prevención / Virus del Papiloma Humano / Vacunación /. Centro de Diagnóstico Colposcópico / Vulvoscopía / Criocirugía / Cono-Leep / Conización Cervical / Cirugía Oncológica /. Programa de Detección de Cancer Ginecológico en Empresas / Distribución de Equipo Med-Gyn /. Cuidados Prenatales / Partos / Nacimientos /. Control de Osteoporosis /. Medicina para la mujer. ONCOMED - COSTA RICA. Prevención del Cáncer de Utero. Cono-Leep / Conización Cervical / Cirugía Oncológica /.

oncomed.net

Onco 360

Thank you for your interest. OncoMed.net has moved to Onco360.com. To visit us at our new and improved site. Onco360 and OncoMed are part of the same company. OncoMed is the JCAHO-accredited dispensing pharmacy of Onco360. Pharmacy: 1-877-662-6633 Pharmacy Fax: 1-877-662-6355. OncoMed Pharmacy is Accredited by:. National Association of Specialty Pharmacy. Onco360, OncoRx, OncoSource, OncoDose, OncoMTM, OncoPaths, OncoAdvocate, OncoNet, and the Onco360 logo are trademarks of Sina Drug Corporation.

oncomed12octubre.blogspot.com

Residentes Oncología Médica Hospital 12 Octubre

Residentes Oncología Médica Hospital 12 Octubre. Martes, 1 de febrero de 2011. Programa docente residentes OM. Programa Oficial de la Especialidad Oncología Médica. Los objetivos de las rotaciones junto con material docente se pueden consultar pinchando aquí. Documentación para evaluación del residente:. Ficha 1 de valoración del residente por la unidad docente. Ficha de valoración de la rotación por parte del residente. Plantilla de la memoria anual del residente. Enviar por correo electrónico. Luis Rob...